Every year, billions of dollars are spent treating smoking and related conditions, yet smoking-related morbidity and mortality continue to rise. There are currently only three FDA-approved medications for smoking cessation: nicotine replacement therapy, bupropion, and varenicline. Although these medications increase abstinence rates, most individuals relapse following treatment. This chapter reviews clinical trials published within the past 10 years investigating novel smoking cessation pharmacotherapies. Among these pharmacotherapies, some showed promising results, such as cytisine and endocannabinoid modulators, whereas others failed to produce significant effects. More research is needed to develop drugs that produce higher rates of long-term abstinence and to determine which subgroups of patients benefit from a given treatment.
CITATION STYLE
Gendy, M. N. S., Ibrahim, C., Sloan, M. E., & Le Foll, B. (2020). Randomized clinical trials investigating innovative interventions for smoking cessation in the last decade. In Handbook of Experimental Pharmacology (Vol. 258, pp. 395–420). Springer. https://doi.org/10.1007/164_2019_253
Mendeley helps you to discover research relevant for your work.